Abstract
Ferroptosis, a therapeutic strategy for tumours, is a regulated cell death characterised by the increased accumulation of iron-dependent lipid peroxides (LPO). Tumour-associated long non-coding RNAs (lncRNAs), when combined with traditional anti-cancer medicines or radiotherapy, can improve efficacy and decrease mortality in cancer. Investigating the role of ferroptosis-related lncRNAs may help strategise new therapeutic options for breast cancer (BC). Herein, we briefly discuss the genes and pathways of ferroptosis involved in iron and reactive oxygen species (ROS) metabolism, including the XC−/GSH/GPX4 system, ACSL4/LPCAT3/15-LOX and FSP1/CoQ10/NAD(P)H pathways, and investigate the correlation between ferroptosis and LncRNA in BC to determine possible biomarkers related to ferroptosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Zu, Xuyu 2 1 University of South China, Cancer Research Institute, The First Affiliated Hospital, Hengyang Medical School, Hengyang, China (GRID:grid.412017.1) (ISNI:0000 0001 0266 8918); University of South China, Department of Clinical Laboratory Medicine, The First Affiliated Hospital, Hengyang Medical School, Hengyang, China (GRID:grid.412017.1) (ISNI:0000 0001 0266 8918)
2 University of South China, Cancer Research Institute, The First Affiliated Hospital, Hengyang Medical School, Hengyang, China (GRID:grid.412017.1) (ISNI:0000 0001 0266 8918)
3 University of South China, Department of Clinical Laboratory Medicine, The First Affiliated Hospital, Hengyang Medical School, Hengyang, China (GRID:grid.412017.1) (ISNI:0000 0001 0266 8918)





